异基因造血干细胞移植术(allo-HSCT)是治疗血液系统恶性及非恶性疾病常见的治疗方法,而allo-HSCT后常见慢性移植物抗宿主病(cGVHD)干眼等眼部并发症,严重影响患者的生存质量,严重者可能会导致角膜穿孔甚至盲。随着allo-HSCT技术不断成熟,移植人数逐渐增多、移植后患者生存时间延长,cGVHD干眼的发生率也不断升高。目前对该病的发病机制、诊断及治疗方面的研究尚不完善,生物标志物的研究对其早期预防、诊断及治疗具有极其重要的作用。本文主要从泪腺、角结膜、睑板腺、泪液及外周血中cGVHD干眼的生物标志物研究进展做一综述。
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common treatment for hematological malignant and non-malignant diseases.However, dry eye, ocular chronic graft-versus-host disease (cGVHD) and other common ocular complications related to cGVHD after allo-HSCT, can seriously affect the quality of life of patients, and may lead to corneal perforation or even blindness in severe cases.With the constant development of allo-HSCT, the incidence of cGVHD-related dry eye is on the rise with the increasing number of patients and the prolonged survival time after transplantation.The pathogenesis, diagnosis and treatment for the disease still remain poorly understood and studied.Biomarkers are of importance for the early prevention, diagnosis and active treatment of cGVHD-related dry eye at present.Progress of biomarkers for cGVHD-related dry eye after HSCT including lacrimal glands, cornea and conjunctiva, meibomian glands, tears and the peripheral blood were reviewed.
王春苗,张琪. 慢性移植物抗宿主病干眼相关生物标志物[J]. 中华实验眼科杂志,2022,40(05):470-474.
DOI:10.3760/cma.j.cn115989-20190121-00025版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。